HomeFUNDING

FUNDING

Procyrion Closes $57.7 Million in Series E Financing

Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.

PhotoniCare Achieves More Than $7 Million in Funding for Commercial Expansion of First-In-Class Ear Imaging Technology

PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.

Vicarious Surgical Raises An Additional $13.2 Mil in Capital

Vicarious Surgical added Philip Liang and Ric Fulop to their Board of Directors. 

Nalu Medical Announces $65 Million Equity Financing to Advance Treatment for Chronic Neuropathic Pain

“Nalu Medical has made tremendous strides commercially and clinically in the past two years. Novo’s investment in Nalu reflects that progress and the confidence they share in the strong commercial potential for Nalu,” observed Geoff Pardo of Gilde Healthcare and Chairman of the Nalu Board.

Neurolief Announces Strategic Equity Investment by Sawai Group Holdings

Mitsuo Sawai, CEO of Sawai Group Holdings, highlighted their commitment to improving patient care and expanding treatment options for migraine and depression through the introduction of Relivion® for at-home treatment under doctor supervision.

LUMA Vision Announces $22 Million in New Financing to Secure FDA Approval and Advance Development of 4D Cardiac Imaging and Navigation Platform

The Series A3 financing added three new investors comprising an undisclosed multinational strategic investor, Atlantic Bridge Growth Fund and Bayern Kapital, and was led by existing investors EQT Lifesciences, ABV Uni Fund and imec.xpand. The new funding adds to prestigious grants won earlier by LUMA Vision from the Irish government’s Disruptive Technologies Innovation Fund ($6 million) and the European Union’s EIC Accelerator ($3 million).

Kazia Therapeutics Announces $2 Million Registered Direct Offering

Kazia has also agreed to issue in a concurrent private placement unregistered warrants to purchase up to an aggregate of 4,444,445 ADSs. The warrants will have an exercise price of $0.583 per ADS, will be immediately exercisable upon issuance, and will expire five and one-half years from the date of issuance. The closing of the offering is expected to occur on or about December 5, 2023, subject to the satisfaction of customary closing conditions.

Savage Medical Exits Stealth With Over $3 Million to Enable Minimally Invasive Colorectal Tumor Removal

The groundbreaking ColoSeal System™ enables minimally invasive colorectal tumor removal, eliminating the need for 2 open surgeries in today's standard of care notes Savage Medical.

Alto Neuroscience Closes $45 Million in Oversubscribed Series C Financing

Alto Neuroscience advises the funds will be used to support ongoing and planned late-stage clinical development of CNS product candidates with four Phase 2 readouts expected across the next 12-18 month